ArticleFrontiers in cardiovascular medicine2026
Ticagrelor plasma concentration, metabolite ratio, and LDH level as independent risk factors for ticagrelor-induced dyspnea in ACS patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ticagrelor-induced dyspnea is a significant clinical concern and is associated with adverse outcomes. However, the specific risk factors leading to ticagrelor-induced dyspnea have not been fully elucidated. This study aims to identify risks by testing plasma concentrations of ticagrelor and its active metabolite, as well as other clinical factors that contribute to the risk. Methods: A total of 102 patients undergoing antiplatelet therapy (ticagrelor and aspirin) were enrolled, including 23 who developed ticagrelor-induced dyspnea and 79 who did not. Plasma levels of ticagrelor and its active metabolite, AR-C124910XX, were measured using high-performance liquid chromatography (HPLC). Clinical characteristics of all enrolled patients were collected completely. The influencing factors of ticagrelor-induced dyspnea were analyzed using logistic regression analysis, and the correlation between patient characteristics and plasma peak concentrations was examined using correlation analysis. Results: Compared with the non-dyspnea group, LDH levels and the ticagrelor metabolite ratio (AR-C124910XX/ticagrelor concentration ratio, TMR) decreased markedly in patients who developed dyspnea (LDH: Conclusion: The peak concentration of ticagrelor, plasma LDH level, and the TMR are important risk factors for associated with ticagrelor-induced dyspnea in ACS patients. The plasma concentration of ticagrelor is negatively correlated with the level of LDH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.